
Please try another search
Tryptamine Therapeutics Limited, a clinical-stage pharmaceutical development company, focuses on developing synthetic psilocybin-related molecules in Australia, Canada, Switzerland, and the United States. The company’s lead program candidate TRP-8803, a proprietary formulation of IV-infused psilocin that completed Phase 2 clinical trial for the treatment of binge eating disorder, fibromyalgia, irritable bowel syndrome, abdominal pain, and visceral tenderness. It is also involved in the development of TRP-8802, a synthetic and oral psilocybin, currently under phase 2a clinical stager for the treatment of binge eating, as well as under phase 2 clinical stage for the treatment of fibromyalgia, and irritable bowel syndrome. The company was founded in 2019 and is based in Camberwell, Australia.
Name | Age | Since | Title |
---|---|---|---|
P. Gage Jull | 65 | 2020 | Independent Non-Executive Director |
Robin L. Carhart-Harris | - | 2021 | Chairman of Scientific Advisory Board |
Joel Castellanos | - | 2021 | Member of Scientific Advisory Board |
William K. Schmidt | 74 | 2021 | Member of Scientific Advisory Board |
Daniel J. Clauw | - | 2021 | Member of Scientific Advisory Board |
Christopher Leo Ntoumenopoulos | 42 | 2024 | Executive Director |
Daniel Tillett | - | 2024 | Non-Executive Director |
David Castle | - | 2024 | Member of Scientific Advisory Board |
Herwig Janssen | - | 2025 | Non-Executive Chairman |
Jason Carroll | - | 2023 | MD, CEO & Executive Director |
Phillipa Hay | - | 2024 | Member of Scientific Advisory Board |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review